Intraperitoneal chemotherapy versus no treatment in patients with ovarian carcinoma who are in complete clinical remission

Background. The optimal management of patients with ovarian carcinoma who are in complete clinical remission after completion of postoperative cisplatin‐based chemotherapy has not been established.

[1]  N. Weiss,et al.  Second thoughts about second-look laparotomy in advanced ovarian cancer. , 1990, The New England journal of medicine.

[2]  H. Averette,et al.  Ovarian carcinoma.Advances in diagnosis, staging, and treatment , 1990, Cancer.

[3]  G. Blackledge,et al.  A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West Midlands Ovarian Cancer Group Trial II. , 1990, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  M. Modan,et al.  Intraperitoneal cisplatin chemotherapy versus abdominopelvic irradiation in ovarian carcinoma patients after. Second‐look laparotomy , 1989, Cancer.

[5]  G. Blackledge,et al.  FAILURE OF SECOND-LOOK LAPAROTOMY TO INFLUENCE SURVIVAL IN EPITHELIAL OVARIAN CANCER , 1988, The Lancet.

[6]  P. Schwartz,et al.  Evaluation of the role of second‐look surgery in ovarian cancer , 1988, Obstetrics and gynecology.

[7]  J. Hainsworth,et al.  Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. , 1988, Annals of internal medicine.

[8]  M. Dudzinski,et al.  Another look at the second-assessment procedure for ovarian epithelial carcinoma. , 1987, American journal of obstetrics and gynecology.

[9]  M. Modan,et al.  Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy. , 1986, Gynecologic oncology.

[10]  N. Sneige,et al.  Prognosis of surgically determined complete responders in advanced ovarian cancer , 1985, Cancer.

[11]  C. Cohen,et al.  Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). , 1983, American journal of obstetrics and gynecology.

[12]  J. Mckinna,et al.  Second-look operations in the planned management of advanced ovarian carcinoma. , 1982, American journal of obstetrics and gynecology.

[13]  S. Nader.  Letter: Storage and transport of serum for prolactin radioimmunoassay. , 1974, Lancet.